Tapia v. Davol, Inc. et al, No. 3:2015cv00179 - Document 26 (S.D. Cal. 2015)
Court Description: ORDER Granting in part and Denying in part 21 Defendant's Motion to Dismiss. Defendants are directed to file an answer as provided in the Federal Rule of Civil Procedure. The hearing set for November 6, 2015 is vacated. Signed by Judge Gonzalo P. Curiel on 11/6/2015. (srm)
Download PDF
<![CDATA[
Tapia v. Davol, Inc. et al Doc. 26 1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 JESUS TAPIA, an individual, 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 vs. CASE NO. 15cv179-GPC(JLB) Plaintiff, DAVOL, INC., a corporation; BARD DEVICES INC., a corporation; C.R. BARD, INC., a corporation, and DOES 1-50, ORDER GRANTING IN PART AND DENYING IN PART DEFENDANTS’ MOTION TO DISMISS [Dkt. No. 21.] Defendants. Before the Court is Defendants Davol, Inc.’s, Bard Devices, Inc. and C.R. Bard, Inc.’s (“Defendants”) motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6). (Dkt. No. 21.) An opposition was filed on October 2, 2015. (Dkt. No. 23.) A reply was filed on October 9, 2015. (Dkt. No. 24.) Based on a review of the first amended complaint, the briefs and the applicable law, the Court GRANTS in part and DENIES in part Defendants’ motion to dismiss. Factual Background On January 27, 2015, Plaintiff Jesus Tapia (“Plaintiff”) filed a complaint against Defendants Davol, Inc., Bard Devices, Inc., and C.R. Bard, Inc. for personal injuries suffered as a proximate result of Defendants’ “negligent and wrongful conduct in connection with the design, development, manufacture, testing, packaging, promoting, marketing, distribution, labeling, sale, and/or post-market surveillance and corrective -1- [15cv179-GPC(JLB)] Dockets.Justia.com 1 action of the Bard Composix Kugel Hernia Repair Patch” (“Kugel Patch” or “Patch”). 2 (Dkt. No. 1, Compl. ¶ 1.) On July 28, 2015, the Court granted in part and denied in 3 part Defendant Davol, Inc.’s1 motion to dismiss with leave to amend. (Dkt. No. 13.) 4 On August 14, 2015, Plaintiff filed a first amended complaint (“FAC”). (Dkt. No. 19.) 5 The allegations in the first amended complaint are almost identical to the facts of the 6 original complaint. 7 Defendants manufactured and sold the Kugel Patch for use in repairing hernias. 8 (Dkt. No. 19, FAC ¶ 2.) The Kugel Patch at issue was manufactured and sold by 9 Defendants between 2001 and March 2006. (Id. ¶ 22.) The Kugel Patch is a prosthetic 10 device used primarily to repair ventral and inguinal hernias. (Id. ¶ 23.) The Patch is 11 composed of two sides where one side is constructed of a double layer of monofilament 12 polypropylene (mesh), and the other side is a barrier of expanded 13 polytetrafluoroethylene (ePTFE). (Id.) This double layer creates a positioning pocket, 14 in which a polymer “memory recoil ring” is placed. (Id.) During the hernia repair 15 surgery, the Kugel Patch is inserted behind the hernia defect through a small incision. 16 (Id.) The memory recoil ring then allows the Kugel Patch to swing open and maintain 17 its shape during placement. (Id.) 18 In October 2000, Defendants submitted a section 510(d) notification of intent to 19 market the Kugel Patch with the Federal Drug Administration (“FDA”). (Id. ¶ 24.) 20 The FDA approved the Kugel Patch for marketing as a Class II medical device in 21 January 2001. (Id.) Immediately after the Kugel Patch was placed on the market, 22 Defendants became aware and obtained knowledge it was defective and causing serious 23 injury to those persons in whom it had been implanted. (Id. ¶ 25.) 24 Defendants were required to conduct post market surveys as part of the device 25 validation process. (Id. ¶ 26.) On or about January 2006, the FDA inspected a Kugel 26 Patch manufacturing facility which resulted in the FDA issuing an Establishment 27 1 At the time, Defendants Bard Devices, Inc. and C.R. Bard, Inc. had not yet been 28 served with the complaint. (Dkt. No. 13 at 1 n. 1.) Since then, Defendants Bard Devices, Inc. and C.R. Bard, Inc. waived service. (Dkt. Nos. 14, 15.) -2- [15cv179-GPC(JLB)] 1 Inspection Report (“2006 EIR”). (Id.) The 2006 EIR found that the post market survey 2 validation process of the device was incomplete and failed to include all data from 3 physicians surveyed during this time, including those which demonstrated unfavorable 4 or “dissatisfied” results. (Id.) According to Plaintiff, these complaints and concerns 5 of physician surveyors were actively concealed by Defendants from Plaintiff, the 6 healthcare community, and other consumers. (Id.) 7 No later than September 2004, Defendants became aware of serious problems 8 with the weld process involving the memory recoil ring. (Id. ¶ 27.) Despite attempts 9 to correct the problem, the corrective measures were ineffective and the process was 10 still not in control. (Id.) Defendants were aware that these weld issues had existed 11 from the time the Kugel Patch was placed on the market and all current sizes and lots 12 suffered from this defect. (Id.) Plaintiff alleges this information was intentionally 13 withheld from Plaintiff, the healthcare community, the FDA, and other consumers. 14 (Id.) 15 According to the 2006 EIR, Davol corporate executives informed the FDA that 16 the spring and summer period of 2005 showed a marked increase in the number of 17 adverse event complaints regarding the Kugel Patch and the memory recoil ring. (Id. 18 ¶ 28.) As of August 2005, Defendants received at least the following adverse event 19 reports: seventeen (17) instances of ring breaks, at least one of which resulted in death; 20 two (2) unexplained bowel perforations; four (4) ring breaks during implant 21 procedures; five (5) cases of device deformity; and eight (8) instances of bowel 22 adhesions to the Patch. (Id.) 23 Despite the increasing number of complaints and complications arising from the 24 Kugel Patch, Defendants failed to cease distribution or notify Plaintiffs, physicians, 25 hospitals, the FDA, or other consumers of the severity of complications associated with 26 the unreasonably dangerous and defective Kugel Patch until late December 2005. (Id. 27 ¶ 29.) 28 In December 2005, there was a limited recall of “Extra Large” sized Kugel -3- [15cv179-GPC(JLB)] 1 Patches even though Defendant knew that there were similar serious adverse events as 2 to the nonrecalled Kugel Patch sizes. (Id. ¶ 30.) Defendants also violated federal law 3 by not timely notifying the FDA of the December 2005 recall. (Id.) 4 The FDA classified the December 2005 recall as a Class 1 recall which is the 5 most serious type of recalls and involve situations where the FDA believes there is a 6 reasonable probability that use of the product will cause serious injury or death. (Id. 7 ¶ 31.) 8 The recall was due to the breakage of the memory recoil ring that opens the 9 Kugel Patch, under stress or pressure, including the stress of implantation. (Id. ¶ 32.) 10 The Kugel Patch is also known to become deformed and migrate within the body. (Id.) 11 These defects are known to cause severe injuries including, inter alia, perforation of 12 the bowel, ring migration through the abdominal wall, abnormal chronic enteric 13 fistulae, infection, abscesses, bowel obstruction, intense abdominal pain, peritonitis, 14 sepsis, and adhesions between the bowel and the Patch. (Id.) The following conditions 15 are symptoms of these injuries: fever, unexplained or persistent abdominal tenderness, 16 vomiting, abnormal bowel movements, tenderness at implant site, abdominal 17 distention, or other unusual symptoms. (Id.) 18 On March 24, 2006, Defendants expanded the recall to include the following 19 Kugel Patch sizes: 1) “Oval” Patches, 2) “Large Circle” Patches, and 3) “Large Oval” 20 Patches. (Id. ¶ 34.) In January 2007, Defendants expanded the recall for the second 21 time, to include further production lots of the “Large Oval” and “Large Circle” Kugel 22 Patches. (Id. ¶ 35.) 23 The FDA inspected the Cranston, Rhode Island Kugel Patch manufacturing 24 facility for the second time from January 23, through March 13, 2007. (Id. ¶ 36.) On 25 April 24, 2007, the FDA issued a “Warning Letter” to Defendants that the inspection 26 again uncovered “serious violations of the law” with regards to the quality assurance 27 programs used in manufacturing the Kugel Patch. (Id.) 28 These violations were of such a degree and nature that the FDA determined the -4- [15cv179-GPC(JLB)] 1 Kugel Patch to be “adulterated” under section 501(h) of the Federal Food, Drug and 2 Cosmetic Act. (Id.) The warning letter specifically mentions, inter alia, the following 3 violations: 4 a. Failure to establish and maintain adequate corrective and preventative 5 action procedures which ensure identification of actions needed to correct and prevent 6 the recurrence of nonconforming product and other quality problems; 7 b. Failure to establish adequate management controls to ensure that an 8 effective quality system has been established and maintained; 9 c. Failure to document the implementation of corrective and preventative 10 actions; 11 d. Failure to validate your device’s design to ensure that the device conforms 12 to defined user needs and intended uses; 13 e. Failure of your firm to establish procedures to completely address the 14 identification, documentation, evaluation, segregation, disposition and investigation 15 of non-conforming product. 16 (Id.) 17 Around December 15, 2005, Plaintiff Jesus Tapia underwent a hernia repair 18 procedure during which a Bard Composix Kugel Hernia Patch (Ref. # 0010202, Lot # 19 43IPD472) was implanted. (Id. ¶ 37.) On or about January 27, 2013, Plaintiff Jesus 20 Tapia was admitted to the emergency department at Menifee Valley Medical Center. 21 (Id. ¶ 39.) He presented with redness and pain above his Kugel Patch surgical site. 22 (Id.) He was diagnosed with abdominal wall mesh infection and abscess. (Id.) Around 23 February 3, 2013, Plaintiff underwent emergency surgery to remove the Kugel Patch. 24 (Id. ¶ 40.) During the removal procedure, it was noted that the plastic ring that 25 supported the Kugel Patch broke and caused an enterotomy which led to Kugel Patch 26 infection. (Id.) 27 As a result, Plaintiff will require continuous monitoring of his Kugel Patch 28 related injuries for the remainder of his life. (Id. ¶ 42.) His physical injuries, -5- [15cv179-GPC(JLB)] 1 proximately caused by his implantation with a Kugel Patch, are severe, life threatening, 2 and permanent, and have adversely impacted the quality of his life. (Id.) 3 The FAC alleges the following causes of action: 4 Count I: Product Liability - Negligence; 5 Count II: Product Liability - Manufacturing Defect; 6 Count III: Product Liability - Failure to Warn; 7 Count IV: Product Liability - Breach of Express Warranty; and 8 Count V: Fraud and Deceit 9 (Dkt. No. 19, FAC.) Defendants move to dismiss Counts III, IV, and V of the FAC. 10 (Dkt. No. 21.) Plaintiff opposed and Defendants filed a reply. (Dkt. Nos. 23, 24.) 11 Discussion 12 A. Legal Standard on Federal Rule of Civil Procedure 12(b)(6) 13 Federal Rule of Civil Procedure (“Rule”) 12(b)(6) permits dismissal for “failure 14 to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). Dismissal 15 under Rule 12(b)(6) is appropriate where the complaint lacks a cognizable legal theory 16 or sufficient facts to support a cognizable legal theory. See Balistreri v. Pacifica Police 17 Dep’t., 901 F.2d 696, 699 (9th Cir. 1990). Under Rule 8(a)(2), the plaintiff is required 18 only to set forth a “short and plain statement of the claim showing that the pleader is 19 entitled to relief,” and “give the defendant fair notice of what the . . . claim is and the 20 grounds upon which it rests.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 21 (2007). 22 A complaint may survive a motion to dismiss only if, taking all well-pleaded 23 factual allegations as true, it contains enough facts to “state a claim to relief that is 24 plausible on its face.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Twombly, 25 550 U.S. at 570). “A claim has facial plausibility when the plaintiff pleads factual 26 content that allows the court to draw the reasonable inference that the defendant is 27 liable for the misconduct alleged.” Id. “Threadbare recitals of the elements of a cause 28 of action, supported by mere conclusory statements, do not suffice.” Id. “In sum, for -6- [15cv179-GPC(JLB)] 1 a complaint to survive a motion to dismiss, the non-conclusory factual content, and 2 reasonable inferences from that content, must be plausibly suggestive of a claim 3 entitling the plaintiff to relief.” Moss v. U.S. Secret Serv., 572 F.3d 962, 969 (9th Cir. 4 2009) (quotations omitted). In reviewing a Rule 12(b)(6) motion, the Court accepts as 5 true all facts alleged in the complaint, and draws all reasonable inferences in favor of 6 the plaintiff. al-Kidd v. Ashcroft, 580 F.3d 949, 956 (9th Cir. 2009). 7 Where a motion to dismiss is granted, “leave to amend should be granted ‘unless 8 the court determines that the allegation of other facts consistent with the challenged 9 pleading could not possibly cure the deficiency.’” DeSoto v. Yellow Freight Sys., Inc., 10 957 F.2d 655, 658 (9th Cir. 1992) (quoting Schreiber Distrib. Co. v. Serv-Well 11 Furniture Co., 806 F.2d 1393, 1401 (9th Cir. 1986)). In other words, where leave to 12 amend would be futile, the Court may deny leave to amend. See Desoto, 957 F.2d at 13 658; Schreiber, 806 F.2d at 1401. 14 B. Count III, Failure to Warn; Count IV, Breach of Express Warranty; Count 15 V, Fraud and Deceit 16 Defendants argue that the FAC fails to adequately allege causation as to the 17 causes of action for failure to warn, breach of express warranty, and fraud and deceit 18 because Plaintiff only changed the term “the healthcare community” and “physicians” 19 to “his healthcare providers” and “his prescribing physician.” They contend that he 20 has not pleaded any additional facts regarding causation. Plaintiff contends that the 21 FAC has sufficiently alleged causation as to all three causes of action. 22 Under the learned intermediary doctrine, the duty to warn in the case of medical 23 devices runs to the physician, not the patient. Plenger v. Alza Corp., 11 Cal. App. 4th 24 349, 362 (1992). A manufacturer fulfills its duty to warn if it provides adequate 25 warnings to the physician. Id. at 362 n. 6 (citing cases); see also Brown v. Superior 26 Court, 44 Cal.3d 1049, 1062 n. 9 (1998). In order to prove causation, Plaintiff must 27 allege that an inadequate warning about the medical device risk would have altered the 28 prescribing physician’s decision to use the product. Motus v. Pfizer, Inc., 196 F. Supp. -7- [15cv179-GPC(JLB)] 1 2d 984, 991 (C.D. Cal. 2001); Motus v. Pfizer Inc., 358 F.3d 659, 661 (9th Cir. 2004) 2 (“[A] product defect claim based on insufficient warnings cannot survive summary 3 judgment if stronger warnings would not have altered the conduct of the prescribing 4 physician.”). The learned intermediary doctrine also applies to breach of warranty 5 claims predicated on a failure to warn claim, see Carlin v. Superior Court, 13 Cal. 4th 6 1104, 1118 (1996), and fraudulent concealment. See Jones v. Medtronic, 89 F. Supp. 7 3d 1035, 1048-49 (D. Az. 2015) (granting motion to dismiss fraud claim since there 8 was no allegation the defendant fraudulently induced her doctor to use defendants 9 products in her surgeries). 10 The original complaint referenced “physicians” and the “healthcare community” 11 in general. In the Court’s prior order granting in part and denying in part Defendant’s 12 motion to dismiss, it held that Plaintiff sufficiently alleged what Defendants failed to 13 warn about, the terms of the express warranty, and as to fraudulent concealment, 14 “what” was concealed, “when” it was concealed and “why” it was concealed. 15 However, in granting Defendant’s motion to dismiss, the Court concluded that as to the 16 three causes of action, Plaintiff failed to allege that his own prescribing physician was 17 not adequately warned, that his own prescribing physician read and relied on the 18 express warranties contained in the packaging and written advertisements, and that his 19 own prescribing physician would not have used the device had Defendants not 20 concealed material facts. (Dkt. No. 13 at 9-10, 16-17, 20.) 21 Defendants argue that replacing the words “physicians” and the “healthcare 22 community” in general to “his prescribing physicians” is not sufficient to satisfy the 23 12(b)(6) standard because Plaintiff fails to provide any additional factual allegations 24 regarding causation such as the circumstances surrounding Plaintiff’s physician’s 25 decision to use the Patch. Specifically, Defendants assert, “Plaintiff only alleges in 26 conclusory terms that his physician read and relied on express warranties in the 27 packaging and written advertisements, but Plaintiff does allege any facts regarding 28 which specific advertisements his physician read and relied on, whether he read one or -8- [15cv179-GPC(JLB)] 1 multiple different advertisements, when he read each advertisement, what specific 2 express warranties were contained in each advertisement he read, or what express 3 warranties were contained in the packaging that his physician read and relied on in 4 rendering his treatment decisions.” (Dkt. No. 21-1 at 12.) 5 The Court concludes that Defendants’ argument imposes a standard that goes 6 beyond what is required under Iqbal and Twombly. Moreover, Defendants do not 7 provide cases to support their position that a complaint requires pleading specific facts. 8 Instead, the cases cited by Defendants concerning the issue of causation are in the 9 context of a motion for summary judgment, a standard distinct from a motion to dismiss 10 standard. See Motus v. Pfizer, Inc., 196 F. Supp. 2d 984, 991 (C.D. Cal. 2001); 11 Huntman v. Danek Medical, Inc., No. 97-2155-IEG(RBB), 1998 WL 663362, at *5 12 (S.D. Cal. July 24, 1998); Todd v. Stryker Corp., No. 2:09cv1509-JAM(GGH), 2012 13 WL 2922727, at *4 (E.D. Cal. May 1, 2012). Second, Defendants cite cases 14 concerning whether the labels are sufficient, In re Clorox Consumer Litigation, 894 F. 15 Supp.2d 1224, 1235 (N.D. Cal. 2012), or whether the particulars of the commercial or 16 advertisement are stated with particularity, Nabors v. Google, Inc., 2011 WL 3861893, 17 at *4 (N.D. Cal. Aug. 30, 2011). However, the Court already ruled that Plaintiff’s 18 allegation as to the contents of the failure to warn, and the express warranty were 19 sufficiently pled. Lastly, many cases cited by Defendants concern allegations of no 20 causation, which is distinct from the instant case. See Hawkins v. Medtronic, Inc., No. 21 13CV499 AWI SKO, 2014 WL 346622, at *8 (E.D. Cal. Jan. 30, 2014) (concerning 22 lack of any causal connection between Plaintiff’s injuries and the alleged failure to 23 report adverse events to the FDA as not adequately pled); Knoppel v. St. Jude Medical, 24 Inc., No. SACV 13-383 JVS(ANx), 2013 WL 3803612, at *2-3 (C.D. Cal. May 7, 25 2013) (failure to provide any allegation that the defect caused Plaintiff’s injury); 26 Rhynes v. Stryker Corp., No. 10-5619 SC, 2011 WL 2149095, at *2-3 (N.D. Cal. May 27 31, 2011) (granting motion to dismiss where there was no allegation that plaintiff was 28 injured by alleged defective product); Currier v. Stryker Corp., No. 11cv1203 JAM-9- [15cv179-GPC(JLB)] 1 EFB, 2011 WL 4898501, at *4 (E.D. Cal. Oct. 13, 2011) (case concerning privity for 2 breach of express warranty, not causation); In re Hydroxycut Marketing and Sales 3 Practices Litigation, No. 09MD2087-BTM(AJB), 2010 WL 2839480, at *2 (S.D. Cal. 4 July 20, 2010) (granting motion to dismiss breach of express warranty because there 5 was no allegation that the plaintiff read the language or relied on the language when 6 she bought the product). 7 Here, the FAC has changed the references of “physicians” and “healthcare 8 community” to “his healthcare providers,” (Dkt. No. 19, FAC ¶ 46), and “his 9 prescribing physicians” (id. ¶¶ 73, 85, 96). As to a failure to warn, the FAC alleges 10 that Defendants failed to warn his own prescribing physician and that his own 11 prescribing physician would not have used the Patch if warnings had been given. (Id. 12 ¶ 73.) As to the breach of express warranty, the FAC contends that his prescribing 13 physician read and relied on the express warranties provided in the packaging and 14 written advertisements, and would not have agreed to use the Kugel Patch if his 15 physician had known that the express warranties were not accurate. (Id. ¶ 90.) Lastly, 16 as to fraudulent concealment, Plaintiff complains that his prescribing physician relied 17 on the fraudulent omissions and would not have implanted the Kugel Patch if the true 18 facts had not been intentionally concealed. (Id. ¶ 106.) 19 These allegations have been deemed sufficient on a motion to dismiss. See 20 Baker v. Bayer Healthcare Pharms., Inc., No. C13-490 THE, 2013 WL 6698653, at *5 21 (N.D. Cal. Dec. 19, 2013). In Baker, the district court concluded the Plaintiff had 22 sufficiently alleged facts to withstand a motion to dismiss based on the allegation that 23 “Plaintiff did not have the same knowledge as Defendant and no adequate warning was 24 communicated to her or her physician(s). Had the Plaintiff received adequate warnings 25 regarding Mirena, she would not have had the device implanted.” Id. 26 Accordingly, the Court DENIES Defendant’s motion to dismiss the causes of 27 action for failure to warn, breach of express warranty and fraudulent concealment. 28 - 10 - [15cv179-GPC(JLB)] 1 D. Count V - Fraud/Deceit2 2 Defendants additionally move to dismiss the fraudulent misrepresentation and 3 fraudulent concealment causes of action for failing to satisfy the heightened pleading 4 requirement under Rule 9(b). As to fraudulent concealment, Defendants maintain that 5 Plaintiff has not alleged the role of each Defendant in the concealment. As to 6 fraudulent misrepresentation, Plaintiff has failed to amend the complaint to allege the 7 specific content of the misrepresentations, where they are located, and when and where 8 the misrepresentations were made and by whom.” (Dkt. No. 21-1 at 15.) Plaintiff 9 opposes arguing that he has sufficiently alleged a claim for fraudulent concealment but 10 does not address the claim of fraudulent misrepresentation. 11 In the Court’s prior order concerning fraudulent concealment, the “Court has 12 concluded that Plaintiff has sufficiently alleged facts to support the specific facts of 13 what information was concealed. Plaintiff has only failed to assert causation and the 14 role of each Defendant in the concealment.” (Dkt. No. 13 at 20-21.) The FAC corrects 15 the deficiency of the original complaint and alleges the role of each Defendant in the 16 alleged concealment. (Dkt. No. 19, FAC ¶¶ 97, 98. 99.) Therefore, the Court DENIES 17 Defendants’ motion to dismiss the fraudulent concealment claim. 18 As to fraudulent misrepresentations, the Court, in the prior order, concluded that 19 Plaintiff failed to allege facts with sufficient particularity under Rule 9(b) concerning 20 the specific content of the misrepresentations, where they are located, and when and 21 where the misrepresentations were made and who made them. (See Dkt. No. 13. at 21.) 22 The FAC does not cure the deficiencies noted by the Court and provides no facts 23 concerning any alleged misrepresentations and only summarily alleges 24 misrepresentations made by Defendants. In addition, Plaintiff does not address this 25 issue in his opposition. With no opposition having been filed on this issue, the Court 26 concludes that Plaintiff concedes the dismissal of the fraudulent misrepresentation 27 2 Under fraud/deceit, Plaintiff alleges a cause of action for fraud/deceit which 28 appears to be a claim for “fraudulent concealment” and “fraudulent misrepresentation” as to Defendants Davol, Inc. and C.R. Bard, Inc. (Dkt. No. 19, FAC ¶¶ 93-109.) - 11 - [15cv179-GPC(JLB)] 1 claim. Since Plaintiff conceded this issue in the prior motion to dismiss3 and does not 2 address the deficiency in the FAC in his opposition, the Court GRANTS Defendants’ 3 motion to dismiss the cause of action for fraudulent misrepresentation without leave 4 to amend since amendment would be futile at this time. See Schreiber Distrib., 806 5 F.2d at 1401. 6 E. Punitive Damages 7 Defendants contend that the claim for punitive damages fails because Plaintiff 8 has not provided specific facts showing the requisite oppression, fraud or malice. 9 Plaintiff opposes. 10 California Civil Code section 3294 provides for punitive damages for a violation 11 of state law. 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 (a) In an action for the breach of an obligation not arising from contract, where it is proven by clear and convincing evidence that the defendant has been guilty of oppression, fraud, or malice, the plaintiff, in addition to the actual damages, may recover damages for the sake of example and by way of punishing the defendant. Cal. Civ. Code § 3294. While section 3294 is a substantive standard that Plaintiff must meet in order to obtain punitive damages, alleging facts to support a claim of punitive damages is governed by the Federal Rules of Civil Procedure, and does not require particularity. See Kelly Moore Paint Co., Inc. v. Nat’l Union Fire Ins. Co. of Pittsburgh, PA, Case No. 14cv1797-MEJ, 2014 WL 2119996, at *3 (N.D. Cal. May 21, 2014). A complaint does not need to contain detailed factual allegations but it must plead “enough facts to state a claim to relief that is plausible on its face.” See Twombly, 550 U.S. at 570. Here, FAC alleges punitive damages based on “Defendants’ intentional, willful, knowing, fraudulent, malicious acts, omissions, and conduct, and their complete and total reckless disregard for the public safety and welfare.” (Dkt. No. 19, FAC ¶ 111.) 3 In the prior motion to dismiss, Plaintiff sought leave to supplement the claim for fraudulent misrepresentation once he had the opportunity to depose his prescribing 28 physician. However, seeking leave to supplement in an opposition is not proper and also premature since the prescribing physician has not yet been deposed. - 12 - [15cv179-GPC(JLB)] 1 He further alleges that Defendants intentionally concealed facts regarding the serious 2 risks of harm associated with the use of the product and intentionally downplayed the 3 type, nature and extent of the adverse side effects of the Kugel Patch implant. (Id.) In 4 addition, Defendants had knowledge and were in possession of evidence demonstrating 5 that the Kugel Patch caused serious physical side effects but provided false and 6 misleading information about the product’s safety and efficacy. (Id. ¶ 112.) Further, 7 Defendants failed to provide accurate information and warning to the healthcare 8 community that would have dissuaded physicians from surgically implanting the Kugel 9 Patch and consumers from agreeing to being implanted with the Kugel Patch. (Id. ¶ 10 113.) 11 These allegations, taken as true, that Defendants knowingly concealed facts 12 regarding the serious risk of harm of using the Patch, and expressly warranted that the 13 Patch was safe and fit for use are sufficient to allege a claim of punitive damages. 14 Thus, at this stage of the proceedings, the Court DENIES Defendants’ motion to 15 dismiss the prayer for punitive damages. 16 17 Conclusion Based on the above, the Court GRANTS in part and DENIES in part Defendants’ 18 motion to dismiss. Specifically, the Court DENIES Defendants’ motion to dismiss the 19 failure to warn (Count III); breach of express warranty (Count IV); and fraudulent 20 concealment (Count V) causes of action. The Court also DENIES Defendants’ motion 21 to dismiss claim for punitive damages. The Court also GRANTS Defendants’ motion 22 to dismiss the cause of action for fraudulent misrepresentation (Count V) without leave 23 to amend. Defendants are directed to file an answer as provided in the Federal Rule of 24 Civil Procedure. 25 / / / / 26 / / / / 27 / / / / 28 / / / / - 13 - [15cv179-GPC(JLB)] 1 The hearing set for November 6, 2015 shall be vacated. 2 IT IS SO ORDERED. 3 DATED: November 6, 2015 4 5 HON. GONZALO P. CURIEL United States District Judge 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 - 14 - [15cv179-GPC(JLB)]
]]>
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You
should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
